As VC Investments Rebound In Q2, Skepticism Lingers
This article was originally published in The Pink Sheet Daily
Executive Summary
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
You may also be interested in...
Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC
Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.
Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC
Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.
Euthymics' Sweet Dreams Could Be Realized With $24MM Series A
The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.